Woman walking down hallway

NEWS & MEDIA

PRESS RELEASES NEWS & PERSPECTIVES EXPERT PERSPECTIVES MEDIA RESOURCES

PRESS RELEASES

10-03-2025

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10-01-2025

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
09-29-2025

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
VIEW ALL
Hand holding phone while on computer

NEWS & PERSPECTIVES

Overview

Year:

  • All
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020

Type:

  • All
  • Awards
  • Kura Kommentary
  • Life at Kura
  • Media Coverage

Awards

Kura CEO Troy Wilson Named an EY Entrepreneur Of The Year® 2025 Pacific Southwest Award Winner

Kura Kommentary

Progress By Collaboration: The Development of Kura’s Menin Inhibitor for AML Research

Awards

Achievement in Operational Excellence to Deliver Business Transformation

Media Coverage

Asking the Right Questions in R&D

Media Coverage

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

Media Coverage

Scrip Asks… What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

Kura Kommentary

Thank You, From Kura Oncology

Kura Kommentary

AML World Awareness Day and Kura’s Commitment

Awards

SDUT San Diego Top Workplaces 2024

Kura Kommentary

From Lab to Clinic: The Origin and Journey of Menin Inhibitors for AML Research

Awards

PharmaVoice 100 Top Industry Leaders: Kathy Ford

Awards

2024 Scrip Awards Community Partnership of the Year: Kura Oncology and Life Science Cares

2024 Scrip Awards Executive of the Year: Troy Wilson, Ph.D., J.D.

Awards

Kura Makes Fast Company’s 100 Best Workplaces for Innovators List

Kura Kommentary

Breakthrough Therapy Designation Granted for Ziftomenib in R/R NPM1-Mutant AML

Media Coverage

Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni, Kura Oncology

Life at Kura

Kura Oncology Supports Life Science Cares’ “Food is Medicine” Initiative

Media Coverage

Menin inhibitors seek to debut as newest targeted therapy for leukaemia

Kura Kommentary

Accelerating Bio Innovation 2024

Kura Kommentary

AML World Awareness Day 2024

Awards

2024 Citeline Awards Excellence in Patient Recruitment & Engagement

Media Coverage

Moving Forward, Giving Back: The ROI of Social Impact

Kura Kommentary

Kura CEO Troy Wilson on the Inflation Reduction Act

Life at Kura

Kura Core Values

Media Coverage

Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

Media Coverage

Kura Oncology Reports Preliminary Data From Menin Inhibitor, Chemo Combination Trial in AML

Media Coverage

Kura’s Leukemia Treatment Performs Best When Tacked Onto Existing Combo, New Data Show

Media Coverage

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

Media Coverage

PharmaVoice’s Crystal Ball: Perspectives on the financial future

Media Coverage

Kathy Ford, R.N., B.S.N., Kura COO, on Ordinarily Extraordinary – Conversations with Women in STEM podcast

Media Coverage

Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place

Media Coverage

The Promise of Precision Oncology, Troy Wilson, President & CEO, Kura Oncology

Awards

SDUT San Diego Top Workplaces 2023

Media Coverage

Kura Oncology’s CEO gives an update on Q3 earnings

Awards

2023 Scrip Awards Best Oncology R&D Advance

Awards

PharmaVoice 100 Top Industry Leaders: Teresa Bair, J.D.

Kura Kommentary

CEO Troy Wilson On Giving Back: Empowering Young Minds to Explore Life Sciences

Awards

San Diego Business Journal Leaders of Influence in Life Science 2023 Honorees

Awards

San Diego Business Journal CEO of the Year Awards 2023 Finalists

Kura Kommentary

World Medical Innovation Forum Panel on The Innovation Gap: The Promise of Precision Oncology for Liquid Tumors

Kura Kommentary

What pharma can teach biotech about the life cycle management of a drug

Kura Kommentary

Kura Oncology 2022 Annual Report

Awards

The Medicine Maker Power List 2023: Francis Burrows

Life at Kura

The History and Culture of Kura

Media Coverage

Navigating Dose Optimization Requirements as a Small Biotech

Awards

SDUT San Diego Top Workplaces 2022

Media Coverage

Liquid Biopsies Guide the Development of Cancer Drugs

Life at Kura

COO Kathy Ford on What Makes Kura a Top Workplace

Awards

SDUT San Diego Top Workplaces 2021

Media Coverage

FDA’s Renewed Focus on Oncology Dosing Spooks Investors, but Companies Say They’re Ready

Media Coverage

Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC with HRAS Mutations

Media Coverage

Is This the Dawn of Precision Oncology in Head and Neck Cancer?

Kura Kommentary

CEO Troy Wilson on Sailing Through the Storm: Lessons from the Pandemic

Awards

PharmaVoice 100: Innovator’s Journey

Awards

PharmaVoice 100: Entrepreneurs

Media Coverage

BIO: Kura Oncology CEO Wilson on the power of biotech in the quest beyond KRAS

Kura Kommentary

CEO Troy Wilson on Navigating a Clinical Stage Biopharmaceutical Company Through the Pandemic
Load More

EXPERT PERSPECTIVES ON AML AND ZIFTOMENIB CLINICAL TRIALS

Harry Erba, MD, PhD

Dr. Erba discusses the KOMET-001 Phase 1b safety and tolerability data of ziftomenib, a menin inhibitor, for patients with R/R NPM1-m AML

/in ,
Read more about Dr. Erba discusses the KOMET-001 Phase 1b safety and tolerability data of ziftomenib, a menin inhibitor, for patients with R/R NPM1-m AML

Dr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML

/in ,
Read more about Dr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML

Dr. Erba explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007

/in ,
Read more about Dr. Erba explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007

“Project Optimus encourages optimal biological dosing rather than maximally tolerated dosing.” — Harry Erba, MD, PhD

/in ,
Read more about “Project Optimus encourages optimal biological dosing rather than maximally tolerated dosing.” — Harry Erba, MD, PhD

Amir T. Fathi, MD

NPM1 mutations in acute myeloid leukemia: actionable mutations to inform treatment decisions with clinical trials

/in ,
Read more about NPM1 mutations in acute myeloid leukemia: actionable mutations to inform treatment decisions with clinical trials

Mechanism of action for investigational menin inhibitors, including ziftomenib

/in ,
Read more about Mechanism of action for investigational menin inhibitors, including ziftomenib

Can you give a brief overview of unmet medical needs within NPM1-mutated acute myeloid leukemia?

/in ,
Read more about Can you give a brief overview of unmet medical needs within NPM1-mutated acute myeloid leukemia?

Amer Zeidan, MBBS, MHS

Evaluating ziftomenib in combinations for patients who are newly diagnosed or relapsed/refractory NPM1m or KMT2Ar AML

/in ,
Read more about Evaluating ziftomenib in combinations for patients who are newly diagnosed or relapsed/refractory NPM1m or KMT2Ar AML

MEDIA RESOURCES

Essential assets such as logos and images related to Kura Oncology.

VIEW ALL
Kura's office